Abstract Number: PB0913
Meeting: ISTH 2020 Congress
Background: Hemophilia A (HA) is the most common severe congenital severe bleeding disorders wit high rate of morbidity and mortality. About 30% of the patients develop inhibitor against exogenous factor VIII (FVIII). Inhibitor development is the most challenging complication of the replacement therapy.
Aims: To assess prevalence of FVIII inhibitor in Afghan patients with HA.
Methods: : A total of 107 patients with HA were evaluated for inhibitors. The Nijmegen modiﬁcation of the Bethesda assay was used for inhibitor assay.
Results: Of 107 patients, 11 (~10.3%) were positive for FVIII inhibitor. All patients with inhibitor had severe HA with on-demand therapy.
Conclusions: It seems that low rate of replacement therapy is the main cause of relatively low rate of inhibitor formation in Afghan patients with severe HA.
To cite this abstract in AMA style:Mousavi SH, Mesbah-Namin SA, Jazebi M, Dorgalaeh A, Zeinali S. Inhibitors in Hemophilia: Treatment Challenges in Afghanestan [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/inhibitors-in-hemophilia-treatment-challenges-in-afghanestan/. Accessed May 17, 2021.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/inhibitors-in-hemophilia-treatment-challenges-in-afghanestan/